Do analysts prefer PRTC or BVXP?

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe PureTech Health is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, PRTC or BVXP?

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £4.66M 65.94 -£91.86M -£46.00 N/A Bioventix £12.54M 6.87 £8.12M £140.52 11.74

Which has higher valuation & earnings, BVXP or SCLP?

Bioventix has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventix £12.54M 6.87 £8.12M £140.52 11.74 Scancell £4.71M 49.79 -£6.75M -£0.55 N/A

Is BVXP or SCLP more profitable?

Bioventix has a net margin of 59.30% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Bioventix's return on equity. Company Net Margins Return on Equity Return on Assets Bioventix 59.30% 65.83% 54.07% Scancell -116.98% 90.29% -45.28%

Does the media favor BVXP or SCLP?

In the previous week, Bioventix and Bioventix both had 1 articles in the media. Bioventix's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scancell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BTG or BVXP?

BTG presently has a consensus price target of GBX 160, suggesting a potential upside of 25.98%. Given BTG's stronger consensus rating and higher probable upside, equities research analysts clearly believe BTG is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, BTG or BVXP?

Bioventix has lower revenue, but higher earnings than BTG. Bioventix is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BTG £159.40M 1.28 N/A £6.00 21.17 Bioventix £12.54M 6.87 £8.12M £140.52 11.74

Is BTG or BVXP more profitable?

Bioventix has a net margin of 59.30% compared to BTG's net margin of 0.00%. Bioventix's return on equity of 65.83% beat BTG's return on equity. Company Net Margins Return on Equity Return on Assets BTG N/A N/A N/A Bioventix 59.30% 65.83% 54.07%

Does the media favor BTG or BVXP?

In the previous week, BTG had 4 more articles in the media than Bioventix. MarketBeat recorded 5 mentions for BTG and 1 mentions for Bioventix. BTG's average media sentiment score of 0.03 beat Bioventix's score of 0.00 indicating that BTG is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BTG 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bioventix (BVXP) Competitors

GBX 1,650 +10.00 (+0.61%)

As of 12:00 PM Eastern

Compare

BVXP vs. PRTC, HZD, SCLP, VRP, and BTG

Should you buy Bioventix stock or one of its competitors? MarketBeat compares Bioventix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventix include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Scancell (SCLP), Verona Pharma plc (VRP.L) (VRP), and BTG (BTG). These companies are all part of the "biotechnology" industry.

How does Bioventix compare to PureTech Health?

PureTech Health (LON:PRTC) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	65.94	-£91.86M	-£46.00	N/A
Bioventix	£12.54M	6.87	£8.12M	£140.52	11.74

In the previous week, Bioventix had 1 more articles in the media than PureTech Health. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Bioventix	Neutral

PureTech Health has a beta of 0.788, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe PureTech Health is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

34.6% of PureTech Health shares are held by institutional investors. Comparatively, 21.1% of Bioventix shares are held by institutional investors. 13.4% of PureTech Health shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bioventix has a net margin of 59.30% compared to PureTech Health's net margin of -2,355.32%. Bioventix's return on equity of 65.83% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Bioventix	59.30%	65.83%	54.07%

Summary

Bioventix beats PureTech Health on 8 of the 15 factors compared between the two stocks.

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Bioventix (LON:BVXP) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Bioventix had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Horizon Discovery Group plc (HZD.L). Bioventix's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

21.1% of Bioventix shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bioventix has higher earnings, but lower revenue than Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.87	£8.12M	£140.52	11.74
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Bioventix has a net margin of 59.30% compared to Horizon Discovery Group plc (HZD.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Summary

Bioventix beats Horizon Discovery Group plc (HZD.L) on 8 of the 9 factors compared between the two stocks.

How does Bioventix compare to Scancell?

Bioventix (LON:BVXP) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Bioventix has a net margin of 59.30% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Bioventix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Scancell	-116.98%	90.29%	-45.28%

In the previous week, Bioventix and Bioventix both had 1 articles in the media. Bioventix's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scancell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Scancell has a beta of 0.573, suggesting that its share price is 43% less volatile than the broader market.

21.1% of Bioventix shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 15.5% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.87	£8.12M	£140.52	11.74
Scancell	£4.71M	49.79	-£6.75M	-£0.55	N/A

Summary

Bioventix beats Scancell on 7 of the 11 factors compared between the two stocks.

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) (LON:VRP) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Bioventix has a net margin of 59.30% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc (VRP.L)	N/A	N/A	N/A
Bioventix	59.30%	65.83%	54.07%

In the previous week, Bioventix had 1 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L)'s average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
Verona Pharma plc (VRP.L)	Neutral
Bioventix	Neutral

21.1% of Bioventix shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has higher revenue and earnings than Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A
Bioventix	£12.54M	6.87	£8.12M	£140.52	11.74

Summary

Bioventix beats Verona Pharma plc (VRP.L) on 9 of the 9 factors compared between the two stocks.

How does Bioventix compare to BTG?

BTG (LON:BTG) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Bioventix has a net margin of 59.30% compared to BTG's net margin of 0.00%. Bioventix's return on equity of 65.83% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
Bioventix	59.30%	65.83%	54.07%

BTG presently has a consensus price target of GBX 160, suggesting a potential upside of 25.98%. Given BTG's stronger consensus rating and higher probable upside, equities research analysts clearly believe BTG is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, BTG had 4 more articles in the media than Bioventix. MarketBeat recorded 5 mentions for BTG and 1 mentions for Bioventix. BTG's average media sentiment score of 0.03 beat Bioventix's score of 0.00 indicating that BTG is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BTG	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.7% of BTG shares are owned by institutional investors. Comparatively, 21.1% of Bioventix shares are owned by institutional investors. 19.7% of BTG shares are owned by company insiders. Comparatively, 6.2% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bioventix has lower revenue, but higher earnings than BTG. Bioventix is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.28	N/A	£6.00	21.17
Bioventix	£12.54M	6.87	£8.12M	£140.52	11.74

BTG pays an annual dividend of GBX 4.30 per share and has a dividend yield of 3.4%. Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 9.1%. BTG pays out 71.7% of its earnings in the form of a dividend. Bioventix pays out 106.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

BTG beats Bioventix on 9 of the 16 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVXP vs. The Competition

Export

Metric	Bioventix	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£86.21M	£451.60M	£6.44B	£2.77B
Dividend Yield	9.04%	3.87%	2.69%	6.12%
P/E Ratio	11.74	3.20	23.77	365.54
Price / Sales	6.87	6,606.32	488.50	87,173.10
Price / Cash	30.89	13.13	41.39	27.85
Price / Book	7.18	83.47	9.76	7.68
Net Income	£8.12M	-£96.07M	£3.56B	£5.89B
7 Day Performance	-1.49%	-1.70%	-3.19%	-0.55%
1 Month Performance	-0.60%	0.74%	-0.11%	3.15%
1 Year Performance	-41.07%	70.06%	25.29%	73.57%

Bioventix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVXP Bioventix	N/A	GBX 1,650 +0.6%	N/A	-42.2%	£86.21M	£12.54M	11.74	12
PRTC PureTech Health	1.4574 of 5 stars	GBX 138.80 +0.3%	GBX 508 +266.0%	-9.8%	£337.86M	£4.66M	N/A	300
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
SCLP Scancell	N/A	GBX 23.90 -2.4%	N/A	+136.2%	£248.03M	£4.71M	N/A	51	News Coverage
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventix (BVXP) Competitors

BVXP vs. PRTC, HZD, SCLP, VRP, and BTG

How does Bioventix compare to PureTech Health?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Bioventix compare to Scancell?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Summary

How does Bioventix compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventix (BVXP) Competitors

BVXP vs. PRTC, HZD, SCLP, VRP, and BTG

How does Bioventix compare to PureTech Health?

Which has stronger earnings & valuation, PRTC or BVXP?

Does the media favor PRTC or BVXP?

Which has more volatility and risk, PRTC or BVXP?

Do analysts prefer PRTC or BVXP?

Do institutionals & insiders have more ownership in PRTC or BVXP?

Is PRTC or BVXP more profitable?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Does the media favor BVXP or HZD?

Do insiders & institutionals believe in BVXP or HZD?

Which has better earnings and valuation, BVXP or HZD?

Is BVXP or HZD more profitable?

Summary

How does Bioventix compare to Scancell?

Is BVXP or SCLP more profitable?

Does the media favor BVXP or SCLP?

Which has more risk & volatility, BVXP or SCLP?

Do institutionals and insiders believe in BVXP or SCLP?

Which has higher valuation & earnings, BVXP or SCLP?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Is VRP or BVXP more profitable?

Does the media refer more to VRP or BVXP?

Do insiders and institutionals hold more shares of VRP or BVXP?

Which has preferable valuation & earnings, VRP or BVXP?

Summary

How does Bioventix compare to BTG?

Is BTG or BVXP more profitable?

Do analysts rate BTG or BVXP?

Does the media favor BTG or BVXP?

Do insiders & institutionals believe in BTG or BVXP?

Which has preferable earnings and valuation, BTG or BVXP?

Is BTG or BVXP a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools